Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Liabilities and Shareholders Equity (2016 - 2025)

Bioadaptives' Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $225901.0 for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 13.74% to $225901.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $733224.0, a 95.17% increase, with the full-year FY2025 number at $225901.0, down 13.74% from a year prior.
  • Liabilities and Shareholders Equity hit $225901.0 in Q4 2025 for Bioadaptives, up from $124360.0 in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for BDPT hit a ceiling of $329302.0 in Q3 2023 and a floor of $8735.0 in Q2 2024.
  • Historically, Liabilities and Shareholders Equity has averaged $120603.2 across 5 years, with a median of $107223.0 in 2023.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 85.91% in 2024 and later surged 3019.81% in 2025.
  • Tracing BDPT's Liabilities and Shareholders Equity over 5 years: stood at $148585.0 in 2021, then plummeted by 74.89% to $37314.0 in 2022, then surged by 178.71% to $103998.0 in 2023, then surged by 151.82% to $261885.0 in 2024, then decreased by 13.74% to $225901.0 in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BDPT at $225901.0 in Q4 2025, $124360.0 in Q3 2025, and $272515.0 in Q2 2025.